metricas
covid
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Pretreatment 18F-FDG PET/CT in predicting the survival of patients with hepatic ...
Journal Information
Share
Download PDF
More article options
Original Article
Available online 8 July 2025
Pretreatment 18F-FDG PET/CT in predicting the survival of patients with hepatic neuroendocrine tumors
Pretratamiento 18F-FDG PET/TC para predecir la supervivencia de pacientes con tumores neuroendocrinos hepáticos
Y. Zhanga,e,#, G. Liub,c,d,#, L. Zhongf, B. Lib,c,d,e,
Corresponding author
li.beilei@zs-hospital.sh.cn

Corresponding authors.
, Y. Zhangb,c,d,e,
Corresponding author
zhang.yiqiu@zs-hospital.sh.cn

Corresponding authors.
a Department of Nuclear Medicine, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China
b Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
c Nuclear Medicine Institute of Fudan University, Shanghai, China
d Shanghai Institute of Medical Imaging, Shanghai, China
e Clinical Research Center for Precision medicine of abdominal tumor of Fujian Province, Xiamen, Fujian, China
f Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (5)
Table 1. Neuroendocrine neoplasms classification for HNET.
Tables
Table 2. Cutoff values for the parameters calculated using receiver operating characteristic curve analysis.
Tables
Table 3. Kaplan–Meier analysis for each variable and were compared using the log-rank test.
Tables
Table 4. Univariate analysis for progression-free survival and overall survival.
Tables
Table 5. Multivariate analysis for progression-free survival and overall survival.
Tables
Show moreShow less
Abstract
Objective

To investigate the prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with hepatic neuroendocrine tumors (HNET).

Methods

In total, 41 patients were included in this study. PET-derived metabolic parameters, including maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), of the tumors were measured. Meanwhile, clinical data, including tumor pathological findings such as the Ki-67 index were also assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analyses were performed to predict the prognostic value of clinical variables and PET-derived metabolic parameters in HNET patients. Correlation between PET-derived metabolic parameters and Ki-67 was estimated.

Results

Univariate analyses revealed that among PET-derived metabolic parameters, SUVmax, SUVmean, and TLG were significant prognostic factors for OS (P < .05). Among clinical variables, the Ki-67 index and radical surgical resection were significant factors for both PFS and OS (P < .05). In multivariate analyses, only Ki-67 index was an independent prognostic factor for both PFS and OS (P < .05). Ki-67 index presented correlates with SUVmax and SUVmean (R = 0.566, P < .001, R = 0.493, P = .001, respectively).

Conclusions

In patients with HNET, the Ki-67 index was an independent prognostic factor for both PFS and OS, while SUVmax, SUVmean, and TLG measured on pretreatment 18F-FDG PET/CT scans were prognostic factors for predicting OS. Ki-67 index also presented correlates with SUVmax and SUVmean. 18F-FDG-PET may be useful as quantitative predicting prognostic imaging biomarkers, especially in poorly differentiated HNET.

Keywords:
Hepatic neuroendocrine tumors
2-[18F]-fluoro-2-deoxy-d-glucose
Positron emission tomography/computed tomography (PET/CT)
Resumen
Objetivo

Investigar el valor pronóstico de la tomografía por emisión de positrones/tomografía computarizada (PET/TC) pretratamiento 2-[18F] -fluoro-2-deoxy-d-glucosa (18F-FDG) en pacientes con tumores neuroendocrinos hepáticos (HNET).

Métodos

Se incluyeron 41 pacientes en este estudio. Se midieron los parámetros metabólicos derivados de la PET/TC, incluidos los valores máximos y medios de captación estandarizada (SUVmax y SUVmean, respectivamente), el volumen tumoral metabólico (MTV) y la glucólisis total de la lesión (TLG) de los tumores. Mientras tanto, también se evaluaron los datos clínicos, incluyendo los hallazgos tumorales patológicos como el índice Ki-67. Se evaluaron la supervivencia sin avance (SSA) y la supervivencia general (SG). Se realizaron análisis univariables y multivariados para predecir el valor pronóstico de las variables clínicas y los parámetros metabólicos derivados de la PET/TC en pacientes con HNET. Se estimó la correlación entre los parámetros metabólicos derivados del PET/TC y el Ki-67.

Resultados

Los análisis univariados revelaron que entre los parámetros metabólicos derivados de la PET/TC, SUVmax, SUVmean y TLG fueron factores pronósticos significativos para la SG (P < ,05). Entre las variables clínicas, el índice Ki-67 y la resección quirúrgica radical fueron factores significativos tanto para la SSA como para la SG (P < ,05) En los análisis multivariados, solo el índice Ki-67 fue un factor pronóstico independiente tanto para la SSA como para la SG (P < ,05). El índice Ki-67 presentó correlaciones con SUVmax y suvmedia (R = 0,566, P < ,001, R = 0,493, P = ,001, respectivamente).

Conclusiones

En los pacientes con HNET, el índice Ki-67 fue un factor pronóstico independiente tanto para la SSP como para la SG, mientras que el SUVmax, el SUVmean y el TLG medido en la PET/TC pretratamiento con 18F-FDG fueron factores pronósticos para predecir la SG. El índice Ki-67 también presentó correlaciones con SUVmax y SUVmean. La 18F-FDG-PET/TC puede ser útil como predicción cuantitativa de biomarcadores pronósticos de imagen, especialmente en HNET poco diferenciados.

Palabras clave:
Tumores neuroendocrinos hepáticos primarios
2-[18F]-fluoro-2-desoxid-glucosa
Tomografía por emisión de positrones/tomografía computarizada (PET/CT)

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Member
If you are a member of the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM), you can access the full text of the contents of the Revista Española de Medicina Nuclear e Imagen Molecular through the journal links published on the SEMNIM website (link: http://socios.semnim.es/?ir-a=remnim), after logging in as a member.

If you experience access problems, you can contact the SEMNIM Technical Secretariat by email at secretaria.tecnica@semnim.es or by phone at +34 619 594 780.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools